Clinical Trial: NCT04134936
Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL
Status:
COMPLETEDPhase:
Phase 1| Lead Sponsor: | MorphoSys AG |
| Information Provided By: | MorphoSys AG |
| Last Update Posted: | 2024-10-16 |
Study Overview
Brief Summary
This is an open-label, randomized, multicentre study to evaluate safety and preliminary efficacy of the human anti-CD19 antibody Tafasitamab in addition to R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) or Tafasitamab and Lenalidomide in addition to R-CHOP in adult patients with newly diagnosed, previously untreated Diffuse Large B-cell Lymphoma (DLBCL).
Official Title
Conditions
Intervention / Treatment
- Drug: Tafasitamab
- Drug: Tafasitamab plus lenalidomide
Other Study ID Numbers
- MOR208C107
Start Date (Actual)
Primary Completion Date (Actual)
Study Completion Date (Actual)
Enrollment (Actual)
Study Type
Phase
| Lead Sponsor: | MorphoSys AG |
| Information Provided By: | MorphoSys AG |
| Last Update Posted: | 2024-10-16 |
Study Overview
Brief Summary
This is an open-label, randomized, multicentre study to evaluate safety and preliminary efficacy of the human anti-CD19 antibody Tafasitamab in addition to R-CHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) or Tafasitamab and Lenalidomide in addition to R-CHOP in adult patients with newly diagnosed, previously untreated Diffuse Large B-cell Lymphoma (DLBCL).
Official Title
Conditions
Intervention / Treatment
- Drug: Tafasitamab
- Drug: Tafasitamab plus lenalidomide
Other Study ID Numbers
- MOR208C107